← Leaderboards
Ponsiano Ocama
Infectious Diseases Institute
$1,075,025
Attributed
$1,896,762
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,016,441 · 3
By mechanism
U54$5,119,679 · 1
U01$1,232,605 · 1
R01$664,157 · 1
Top collaborators
- Gregory D Kirk10 shared
- Stefan David Baral4 shared
Most similar at Infectious Diseases Institute
Same institution · by research overlap
- Alex Muganga Muganzi$17,474,179
Others in their field
Other Emerging Leaders on “Universities”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
Research focus
UniversitiesCountryPrimary Carcinoma Of The Liver CellsAfrica South Of The SaharaPersonsResearch PersonnelAfricaUgandaHepatitis B VirusEpidemiologyInfrastructureMortalityFundingCo-InfectionIncidenceInfectionLiverResearch InfrastructureCareer DevelopmentResponseImmune ResponseInvestigationSchistosoma Mansonii InfectionMalignant Neoplasms
Grant awards (15)
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$337,004
U01 · FY2025 · CA
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$223,400
U01 · FY2025 · CA
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$39,960
U01 · FY2025 · CA
HIV and HCC in Africa: The H2A Consortium$987,283
U54 · FY2024 · CA
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$632,241
U01 · FY2024 · CA
Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda$130,925
R01 · FY2024 · AI · contact PI
HIV and HCC in Africa: The H2A Consortium$124,783
U54 · FY2024 · CA
HIV and HCC in Africa: The H2A Consortium$990,369
U54 · FY2023 · CA
Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda$131,009
R01 · FY2023 · AI · contact PI
HIV and HCC in Africa: The H2A Consortium$990,617
U54 · FY2022 · CA
Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda$132,310
R01 · FY2022 · AI · contact PI
HIV and HCC in Africa: The H2A Consortium$988,451
U54 · FY2021 · CA
Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda$134,913
R01 · FY2021 · AI · contact PI
HIV and HCC in Africa: The H2A Consortium$1,038,176
U54 · FY2020 · CA
Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda$135,000
R01 · FY2020 · AI · contact PI